Skip to main content
SpringerLink
Log in

LH-RH Agonists for the Treatment of Breast Cancer

Development and Current Status

  • Chapter
Book cover Hormone Therapy in Breast and Prostate Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 332 Accesses

Abstract

In a momentous discovery arising out of his research, in 1896 Beatson showed that the growth of some breast cancers could be interrupted by oophorectomy (1). He operated on three women, one of whom clearly responded, achieving a remission of 42-mo duration. Interestingly, the response rate in many series since that time has remained close to one in three. Oophorectomy or ovarian irradiation went in and out of fashion, but by the 1960s it was accepted as the standard treatment for premenopausal women with advanced breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii:104–107.

    Article  Google Scholar 

  2. Paterson R, Russell MH. Clinical trials in malignant disease: part II. Breast cancer: value of irradiation of the ovaries. J Fac Radiol 1959; 10:103–133.

    Article  Google Scholar 

  3. Nissen-Meyer R. Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 1991; 2:343–346.

    CAS  PubMed  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348:1189–1196.

    Google Scholar 

  5. Stein JJ. Surgical or irradiation castration for patients with advanced breast cancer. Cancer 1969; 24:1350–1354.

    Article  CAS  PubMed  Google Scholar 

  6. Williams MR, Walker KJ, Blamey RW, et al. The use of an LH-RH agonist (ICI 118630, ‘Zoladex’) in advanced premenopausal breast cancer. Br J Cancer 1986; 53:629–636.

    CAS  PubMed  Google Scholar 

  7. Blamey RW, Jonat W, Kaufmann M, et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992; 28A:810–814.

    Article  CAS  PubMed  Google Scholar 

  8. Furr BJA. Pharmacology of luteinising hormone-releasing hormone (LHRH) analogue, ‘Zoladex’. Horm Res 1989; 32(Suppl 1):86–92.

    Article  CAS  PubMed  Google Scholar 

  9. Veronesi U, Cascinelli N, Greco M, et al. A reappraisal of oophorectomy in carcinoma of the breast. Ann Surg 1981; 205:18–21.

    Google Scholar 

  10. Buchanan RB, Blamey RW, Durrant KR, et al. A randomised comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986; 4:1326–1330.

    CAS  PubMed  Google Scholar 

  11. Ingle JN, Krook JE, Green SJ, et al. Randomised trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986; 4:178–185.

    CAS  PubMed  Google Scholar 

  12. Frachia AA, Farrow JH, DePalo AJ, et al. Castration for primary inoperable or recurrent breast carcinoma. Surg Gynecol Obstet 1969; 128:1226–1234.

    Google Scholar 

  13. Lewison EF. Prophylactic versus therapeutic castration in the total treatment of breast cancer. A collective review. Obstet Gynecol Surv 1962; 17:769–802.

    Article  CAS  PubMed  Google Scholar 

  14. Williamson K, Robertson JFR, Blamey RW. Effect of LHRH agonist, Zoladex on ovarian histology. Br J Surg 1988; 75:595–596.

    Article  CAS  PubMed  Google Scholar 

  15. Klijn JGM, Blamey RW, Boccardo F, et al. A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists’ Group (CHAT). Eur J Cancer 1998; 34:(Suppl 5): S90 Abs 405.

    Article  Google Scholar 

  16. Blamey RW, Jonat W, Kaufmann M, et al. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1993; 29A:1498.

    Article  CAS  PubMed  Google Scholar 

  17. Blamey RW. The introduction of the LHRH agonist, goserelin (‘Zoladex’) into clinical practice. Endocr Rel Cancer 1997; 4:229–232.

    Article  CAS  Google Scholar 

  18. Williams MR, Todd JH, Blamey RW, et al Survival patterns in hormone treated advanced breast cancer. Br J Surg 1986; 75:752–755.

    Article  Google Scholar 

  19. Robertson JFR, Nicholson RI, Blamey RW, et al. Confirmation of a prognostic index or metastatic breast cancer. Breast Cancer Res Treatment 1992; 22:221–227.

    Article  CAS  Google Scholar 

  20. Taylor CW, Green S, Dalton WS, et al. Multicenter randomised clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an Intergroup Study. J Clin Oncol 1998; 16:994–999.

    CAS  PubMed  Google Scholar 

  21. Dixon AR, Jackson L, Robertson JFR, Blamey RW, et al. Combined goserelin and tamoxifen in premenopausal advanced breast cancer Eur J Cancer 1991; 24:806–807.

    Google Scholar 

  22. Robertson, JFR, Walker, KJ, Nicholson RI, Blamey RW, et al. Combined and endocrine effects of LHRH agonist, Zoladex and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br J Surg 1989; 76:1262–1265.

    Article  CAS  PubMed  Google Scholar 

  23. Nicholson RI, Walker KJ, Blamey R, et al. ‘Zoladex’ plus tamoxifen versus ‘Zoladex’ alone in pre- and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol 1990; 37:989–995.

    Article  CAS  PubMed  Google Scholar 

  24. Jonat W, Kaufmann M, Blamey RW, et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995; 31A:137–142.

    Article  CAS  PubMed  Google Scholar 

  25. Klijn JGM, Beex L, Mauriac L, et al. Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ann Oncol 1998; 9(Suppl 4):11(Abs 540).

    Google Scholar 

  26. Boccardo F, Rubagotti A, Perrotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre- perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994; 5:337–342.

    CAS  PubMed  Google Scholar 

  27. Cohen I, Tepper R, Figer A, et al. Successful co-treatment with LHRH agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Cancer Res Treatment 1999; 55:199–125.

    Google Scholar 

  28. Plourde PV, Dyroff M, Dowsett M, et al. ‘Arimidex’: A new, oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995; 53:175–179.

    Article  CAS  PubMed  Google Scholar 

  29. Thuerliman BJK, Nabholtz JM, Bannetone J, Robertson JFR, et al. on behalf of Arimidex Study Group. Preliminary results of two comparative multicentre clinical trials comparing the efficacy and tolerability of Arimidex (anastrazole) and tamoxifen (TAM) in postmenopausal women with advanced breast cancer. Breast 1999; 8:214(Abs).

    Google Scholar 

  30. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83:1142–1152.

    Article  CAS  PubMed  Google Scholar 

  31. Houghton J, Baum M, ATAC Study-Group. ‘Arimidex’, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer. Eur J Cancer 1998; 34 (Suppl 5): S83(Abs 385).

    Article  Google Scholar 

  32. Blamey RW. The role of selective non-steroidal aromatase inhibitors in future treatment strategies. Oncology 1997; 54 (Suppl 2):27–31.

    Article  PubMed  Google Scholar 

  33. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer; an overview of the randomised trials. Lancet 1998; 351:1451–1467.

    Google Scholar 

  34. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer; an overview of the randomised trials. Lancet 1998; 352:930–942.

    Google Scholar 

  35. Jonat W. Luteinizing hormone-releasing hormone analogues: the rationale for adjuvant use in premenopausal women with early breast cancer Br J Cancer 1978; 78 (Suppl 4):5–8.

    Google Scholar 

  36. Baum M, Rutgers E for ZIPP trial. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial Breast 1999; 8:233.

    Google Scholar 

  37. Davidson NE, O’Neill A for ECOG, SWOG and CACGB. Effect of chemohormonal therapy in premenopausal node positive, receptor positive breast cancer (INT-0101) Breast, 1999; 8:232.

    Article  Google Scholar 

  38. Boccardo P, Rubagotti A for Italian Breast Cancer Adjuvant Study Group. CMF vs tamoxifen plus ovarian stimulation as adjuvant treatment of ER positive pre-menopausal breast cancer. Breast 1999; 8:233.

    Google Scholar 

  39. Jakesz R, Gnant M for ABCSG. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone responsive tumours (Abstract).

    Google Scholar 

  40. Jonat W. Eur J Cancer 2000; 36 Suppl. 5:567.

    Article  Google Scholar 

  41. Blamey RW The design and clinical use of the Nottingham Prognostic Index in breast cancer Breast 1996; 5:156–157.

    Article  Google Scholar 

  42. Mastro LD Venturini M, Sertoli R, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications Breast Cancer Res Treatment 1997; 43:183–190.

    Article  Google Scholar 

  43. Sacks NPM, A’Hern RP, Baum M. How much of the effect of chemotherapy is due to hormonal manipulation, in Medical Radiology. Non-Disseminated Breast Cancer (Fletcher GH, & Levitt SH, eds). Springer-Verlag, Berlin, 1993.

    Google Scholar 

  44. Brincker H, Rose C, Rank F. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer J Clin Oncol 1987; 5:1771–1778.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, UK

    Roger W. Blamey

Authors
  1. Roger W. Blamey
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Rd. NW Research Bldg. E501, Washington, DC, 20057, USA

    V. Craig Jordan

  2. AstraZeneca Pharmaceuticals Zeneca Pharmaceutical, Alderly Park, Alderly House, Macclesfield, SK 10 4TF, UK

    Barrington J.A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Blamey, R.W. (2009). LH-RH Agonists for the Treatment of Breast Cancer. In: Jordan, V.C., Furr, B.J. (eds) Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-152-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-152-7_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-471-5

  • Online ISBN: 978-1-59259-152-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation